Pyxis Oncology

Company snapshot

Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes.

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Pyxis Oncology. Not investment advice.

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 46.8

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

• Peer + 0 momentum

  Revolution Medicines

  TA overlap score 25.2

• Peer + 0 momentum

  Astellas Pharma

  TA overlap score 24.4

• Peer + 0 momentum

  Eikon Therapeutics

  TA overlap score 23

• Peer + 0 momentum

  IDEAYA Biosciences

  TA overlap score 22.8

• Peer + 0 momentum

  Topiloric/Uriadec

  TA overlap score 22.4

• Peer + 0 momentum

  TScan Therapeutics

  TA overlap score 21.8

• Peer + 0 momentum

  CytomX Therapeutics

  TA overlap score 21.6

• Peer + 0 momentum

  Turn Therapeutics

  TA overlap score 21.2

Recent activity

Latest pipeline, patent, and corporate events for Pyxis Oncology.

1. Jun 8, 2026 Clinical update

   PYX-201-102 — Phase 2

2. Jun 8, 2026 Clinical update

   PBTC-051 — Phase 1

3. Jun 8, 2026 Clinical update

   Phase 1 Study of PYX-201 in Solid Tumors — Phase 1

4. Jun 8, 2026 Clinical update

   Phase 1 Study of PYX-106 in Solid Tumors — Phase 1

5. Jun 8, 2026 Clinical update

   APX005M — Phase 2

View all clinical trial activity →

• What is Pyxis Oncology?

  Pyxis Oncology is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker PYXS. Primary therapeutic focus areas include Advanced Solid Tumors, Solid Tumor, Solid Tumors, Advanced solid tumors, Melanoma. NovaPharmaNews links 8 clinical program(s), 0 drug

• Is Pyxis Oncology publicly traded?

  Yes. Pyxis Oncology is listed with ticker PYXS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Pyxis Oncology develop or market?

  We link 6 drug profile(s) where Pyxis Oncology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pyxis-oncology#company-drugs.

• What are the latest developments for Pyxis Oncology?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Pyxis Oncology focus on?

  Pyxis Oncology focuses on Advanced Solid Tumors, Solid Tumor, Solid Tumors based on our analysis of their pipeline programs and drug development activities.